Kornimate/medical-research-clean huggingface dataset:
combination of autologous msc and hsc infusion in patients with decompensated cirrhosis

Conditions: Cirrhosis, Liver

Summary: though the results of autologous cd34+ cell infusion and msc in independent studies have shown promise, yet they are yet to reach the desired long term outcome. the possible postulation for this is possibly because when using autologous cd34+ cell infusion, the inflammatory milieu of the liver may not be conducive for sustained effects of the mobilized cd 34+ cells. msc have immunomodulatory effect (ref) and may improve the liver environment making it more beneficial for the cd34+ cells to function and survive. in addition, msc has ben shown to produce hepatocyte growth factor which is protective against liver injury and beneficial for liver regeneration (shown in above tables). however, it remains to be understood how mscs promote liver stem stem cells to differentiate into hepatocytes or expand the residual hepatocyte population. msc can also directly inhibit the activation of hepatic stellate cells, the main source of extracellular matrix via msc derived il 10 and tnf-αand may also induce hepatic stellate cell apoptosis. current lacunae in cell based therapy is based on the poor consensus and understanding on the best type of cells to be used, the ideal number of cells, the most appropriate route of administration and the need for repeat dosing . the concept that combination of autologous hematopoietic and mesenchymal stem cells infusion may be more beneficial than infusing any one of them alone has been discussed in many scientific forums but there are no study till date to either see the safety as well as the efficacy of this proof of concept . with this above background data, we propose a study design which will be a safety study for combination use of autologous cd34+ and msc


Eligibility criteria:
inclusion criteria: * age between 20-70 years * clinically diagnosed for hepatic cirrhosis having a child pugh score of b or meld \>10 but below 20 * not willing for immediate liver transplantation either due to lack of donor tissue or financial issues * platelet count of \> 80,000 and inr \<1.6 * life expectancy of at least 3 months based on meld score and child pugh score * ability to give informed consent exclusion criteria: * age less than 20 or more than 70 years * have liver tumors or history of any other cancer * pregnant or lactating women * patients with hepato-renal syndrome and acute kidney injury (any creatinine \> 1.6 will be excluded) * evidence of ongoing sepsis - as per surviving sepsis guideline * recent gastrointestinal bleeding or spontaneous bacterial peritonitis (within last one month) * any hiv positive patients * co-morbid conditions such as severe cardiac and/or pulmonary disease * inability to give informed consent

Keywords: mesenchymal stem cell hematopoetic stem cell autologous transfusion
a study to assess the quality of bone in patients taking oral ibandronate versus placebo

Conditions: Osteoporosis

Summary: the purpose of this study is to estimate the effect of oral boniva (ibandronate sodium)taken once monthly versus placebo on bone quality and strength at the hip at one year.


Eligibility criteria:
inclusion criteria: * ambulatory, postmenopausal women who are diagnosed with osteoporosis. * must be able to stand or sit upright for at least 60 minutes and swallow a tablet whole. exclusion criteria: * have been treated with other bisphosphonates or using chronic steroids within the past 6 months. * have a history of major upper gi diseases or have severe kidney dysfunction. * have a spine fracture (identified on x-ray).

Keywords: osteoporosis bisphosphonates bone
a comparison of pain severity on injection of mct/lct propofol between lidocaine 20 mg, 40 mg, and without lidocaine.

Conditions: Adult Disease

Summary: to compare the severity of pain on injection of mct/lct propofol with lidocaine 20 mg, 40 mg, and without lidocaine.

background: intravenous injection of propofol produces pain. many factors are involved and various techniques have been tried to minimize the propofol-induce pain with variable results. objective: to compare the severity of pain on injection of mct/lct propofol with lidocaine 20 mg, 40 mg, and without lidocaine. design: randomize controlled trial. method: two hundred and ten asa class i - iii patients undergoing elective surgery were blinded and equally allocated into 3 groups. patients in group n, l1, and l2 received mct/lct propofol 10 ml mixed with 0.9% nacl 2 ml, 1% lidocaine 2 ml, and 2% lidocaine 2 ml respectively. pain at time of propofol injection was assessed by blinded anesthesiologist on a four point scale ; 0 = no pain, 1 = mild pain, 2 = moderate pain, and 3 = severe pain. results: patient's demographic data of each group were similar. there were significant differences in the incidence of propofol injection without pain among groups (p\<0.001). the numbers of patients who had moderate and severe pain in groups l1 and l2 were significantly less than those in group n (p\<0.001). the mean blood pressure and heart rate were not significant differences in among groups. conclusion : the amount of 20 mg, and 40 mg lidocaine to mct/lct propofol in our study is equally effective in decreasing pain and more effective than mct/lct propofol alone group significantly. they were no significant differences in hemodynamics change in among groups.

Eligibility criteria:
inclusion criteria: * asa class i - iii patients * undergoing elective surgery * age 18-75 years exclusion criteria: * allergy to propofol and lidocaine * abnormal liver and renal functions * has psychological problem or drug abuse * has recieved analgesic drug 2 weeks prior to surgery * risk of aspiration
incisional negative pressure wound therapy

Conditions: Spinal Deformity

Summary: the purpose of this study is to evaluate the outcome of incisional negative pressure wound therapy in preventing surgical site infections and wound complications (dehiscence) in high-risk patients undergoing complex spinal surgery.

this randomized, controlled study will compare the outcomes of npwt versus the outcomes of not using npwt in post-operative wound management following a complex spinal surgery. the allocation of patients (no npwt device versus applying an npwt device) will be determined by computer-generated randomization. the following data will be collected to determine impact on the outcome of wound management (i.e., infection and wound dehiscence): age, gender, body mass index (bmi), dorsal fat, estimated blood loss during the surgical procedure, length of surgery, length of hospital stay, highest peri-operative glucose, medical comorbidities, and history of infection.

Eligibility criteria:
inclusion criteria: * \>/= 18 years of age * \>/= 3 level instrumented thoracic, lumbar, or thoracolumbar spinal fusion exclusion criteria: * \< 18 years of age * \< 3 level instrumented thoracic, lumbar, or thoracolumbar spinal fusion * spinal infection at time of surgery * history of immunosuppression or chronic systemic infection * pregnancy * inability to provide informed consent

Keywords: spinal deformity complex spinal surgery negative pressure wound therapy post-operative infection
pain and neck dysfunction following dry needling with and without intramuscular electrical stimulus.

Conditions: Neck Pain; Shoulder Pain; Myofascial Pain

Summary: participants will be 18-59 years old who are recruited through a convenience sample from the umhb/belton community. there will be a randomized control trial consisting of three groups. each participant will be assigned based on their order of entry to the study group assignment and then randomly organized via computer generation into 3 groups of 20 participants including a control group, a dry needling group (dn), and a dry needling e-stim group (dn-es), resulting in approximately 60 total participants. participants in the dn and dn-es groups will be treated four times; at weeks 0, 2, 4 and 6 of the study. data will be collected at weeks 4, 6 and 12 in all groups.

interventions per group: control: none dn: 20-30 seconds of dn per trigger point in each involved trapezius muscle, needles rest in situ 10 min, needles removed. dn-es: 20-30 seconds of dn per trigger point (trp) in each involved trapezius muscle, dc es attached to needles crossing the most reactive trp and current set to strong, but comfortable intensity at 10 mhz for 10 min, needles removed.

Eligibility criteria:
inclusion criteria: 1. 18-59 years old 2. have an active email account 3. have at least one palpable active trigger point (trp) (located in one or both upper trapezius) 4. english speaking exclusion criteria: 1. current treatment or diagnosis related to cancer 2. active local or systemic infection 3. neurologic deficit 4. cognitive deficit 5. pregnancy 6. connective tissue disease and/or autoimmune disorder 7. tobacco use 8. received previous dn treatments within 6 weeks of the study, 9. experienced unilateral or bilateral neck/shoulder pain continuously for 3 months or longer 10. neck disability index score \< 6 11. numerical pain rating scale score \< 3
nurse specialist intervention promoting altered coping and treatment for chronic pain

Conditions: Chronic Pain

Summary: the aim of this study is to investigate of the implementation of an autonomous consultation with a nurse pain specialist for chronic pain patients has an influence on the behaviour towards the chronic pain. the trail will be done with patients that has planned an infiltration in a pain centre. furthermore the pain intensity and patent satisfaction will be investigated as second outcomes. during the consultation there will be explained what the patient can expect from the treatment in the pain clinic. what the patient expect from the infiltration will also be surveyed, so that it can be adjusted if necessary. in the end of the consultation there will be a brief explanation of chronic pain and the physiology as well als the different factors that have an influence on it. this study is a monocentric randomised controlled trail of 172 participants, with an equal allocation (1:1). to collect the data there will be three different questionnaires for both groups. the first is a baseline measurement. the second will take place three weeks after the infiltration and the third ten weeks after the infiltration. this is in order to see if there is an evolution in the outcomes during time.


Eligibility criteria:
inclusion criteria: * patients that have an appointment for a treatment * patients with chronic pain, so 3 months or more and of functional dysfunction because of the pain. * patients that are receiving a spinal treatment form the cervical, thoracic or lumbar spine. * the patient has to understand the dutch language. exclusion criteria: * patients with a neurostimulator, an intrathecal medication pump or patients that already has an appointment at the consultation in the pain clinic. they have an doctor- patient relationship and that can cause bias. * people who are legally incapable (persons younger then 18 years, persons with dementia, other cognitive diseases. * people with facial pain. here is the necessity of quick treatments. or they already take place in other studies. * people who are interned or detained. there is no possibility of follow-up. * palliative, oncologic or in hospital patients * patients who need a emergency treatment, because it is mostly acute or sub acute pain.
study of viral respiratory infections

Conditions: Respiratory Infections

Summary: acute viral respiratory infections are a major public health problem, as they cause mortality especially in pediatric patients, over 65 and those with co-morbidities. the most frequently responsible viruses are: influenza a and b, respiratory syncytial virus, adenovirus, parainfluenza virus, metapneumovirus, rhinovirus and sars-cov-2. by comparing clinical data and laboratory diagnosis among all categories of patients at greatest risk, it is possible to define the symptoms associated with the pathogen and establish which etiological agents could be able to cause clinical pictures characteristics of a given type of patient. the study will also provide information on the potential role that simultaneously detected pathogens may play in determining the severity of the clinical picture. in addition, the results will allow to deepen the changes in seasonality and spread of different respiratory viruses associated with the covid-19 pandemic.

the aim of the study is: 1. calculate the percentage of positive cases during 2018-2023. 2. association between the viral pathogens detected individually or in packaging in respiratory material and: typology of symptomatology/clinical outcome; typology of clinical signs detectable with objective/instrumental examinations; degree of severity of clinical manifestation. 3. reduction in the prescription of instrumental investigations (rx/ecoaddome) and reduction in the prescription of empirical antibiotic therapy with amoxicillin or amoxicillin and clavulanic acid in pediatric patients.

Eligibility criteria:
inclusion criteria: * adult and pediatric patients, of any age, with clinical diagnosis of acute respiratory infections and with request for search of the main respiratory viruses (flua, flub, vrs, adv, piv, mpv, rv and sars-cov-2) * obtaining informed consent where possible. exclusion criteria: * none

Keywords: infection virus respiratory rsv sars-cov-2 flua flub adv mpv piv adenovirus metapneumovirus severe acute respiratory syndrome
two different regimens of bemiparin as a thromboprophylaxis in morbidly obese surgical patients

Conditions: Morbid Obesity

Summary: morbid obesity, is known to be associated with a high risk of vte and, unfortunately, fixed doses of anticoagulant regimens may not provide optimal vte prophylaxis in these patients especially after surgery.

venous thromboembolism (vte) is serious and preventable in patients who have undergone recent surgery . most surgical patients are required to receive vte prophylaxis, usually pharmacologic prophylaxis. notwithstanding, rates of appropriate perioperative thromboprophylaxis remain tenaciously low, although the expansion of quality-improvement efforts has led to widespread hospital implementation of prophylaxis strategies. obesity, including morbid obesity, is known to be associated with a high risk of vte and, unfortunately, fixed doses of anticoagulant regimens (unfractionated heparins, low-molecular-weight heparins, and factor xa inhibitors) may not provide optimal vte prophylaxis in these patients especially after surgery. cumulative evidence and works of the literature suggest that anticoagulant dose adjustments in morbidly obese patients may reduce vte risk. with the increasing rate of morbid obesity, more high-quality clinical trials are needed to prevent vte in morbidly obese surgical patients providing effective, safe, prevention strategies

Eligibility criteria:
inclusion criteria: 1. participants required surgical intervention in: general surgery, gynecology, bariatric surgery 2. moderate, high, and very high risk for venous thromboembolism according to caprin ram 3. participant is willing and able to give informed consent for participation in the study. 4. bmi ≥40kg/m2 exclusion criteria: 1. having any contraindication to lmwh, such as active bleeding, history of heparin-induced thrombocytopenia , baseline platelet count \ 200/120 mmhg) 2. known hypersensitivity to unfractionated or lmwhs 3. on oral or parenteral anticoagulants within 5 days before surgery 4. severe arterial hypertension 5. unable to comply with the study treatment and/or follow-up 6. receiving prohibited medications 7. pregnancy or lactation mother

Keywords: lmwh thromboprophylaxis non-orthopedic surgeries gynecological surgeries general surgeries bariatric surgeries
quality project malnutrition intensive care

Conditions: Malnutrition

Summary: observational study to investigate nutrition state in all admitted patients in icu. measurement by biva and snaq score.

malnutrition is a great problem in healthcare, its related to mortality, infections and length of stay. observational study to investigate nutrition state in all admitted patients in icu. measurement by biva and snaq score. all patients were asked for their nutrition state by snaq and the biva measurement is done by a trained doctor.

Eligibility criteria:
inclusion criteria: * admission icu exclusion criteria: * none

Keywords: biva measurement snaq score
neuronavigation guided itbs with personalized target for depression

Conditions: Depression

Summary: the study will compare the efficacy of intermittent theta burst stimulation (itbs) with dlpfc-pgacc personalized target for major depressive disorder (mdd) and explore possible brain network mechanisms. the stimulated targets will be located by magnetic resonance imaging (mri) based on functional mri based on functional connectivity respectively. this study aims to identify that functional connectivity targeted itbs protocols on dlpfc-pgacc personalized target have a better antidepressant efficacy compared the sham group and certify that pgacc is an effective potential effector target.


Eligibility criteria:
inclusion criteria: * 18 to 60 years old * meet the criteria of the diagnostic and statistical manual of mental disorder- v of mdd, single or recurrent * meet the threshold on the total hamd17 score of \>17 at both screening and baseline visits * able to provide informed consent exclusion criteria: * any other current or past psychiatric axis-i or axis-ii disorders * severe physical illnesses * psychotic symptoms, alcohol or drug abuse * a history of neurological disorders including seizure, cerebral trauma * mri evidence of structural brain abnormalities * contraindications to mri and rtms * acute suicide * female that is pregnant or breastfeeding

Keywords: depression intermittent theta burst stimulation neuronavigation
evaluation of the interest of the medical device called "fluobeam" in the localization, visualization of the parathyroid glands for patients with mild primary hyperparathyroidism

Conditions: Mild Primary Hyperparathyroidism

Summary: the aim of our study is to evaluate the value of the camera called "fluobeam" in the localization, visualization of the parathyroid glands for patients with mild primary hyperparathyroidism.

recently, it has been shown that parathyroid glands presented auto fluorescence, visible in the near infra-red light. parathyroid glands emit at 822 nanometers when they are stimulated by a laser of 785 nanometers. fluoptics company (fluoptics sas, grenoble, france) will provide a camera called "fluobeam", facilitating the visualization of the parathyroid glands. the fluorescence intensity of the parathyroid glands is much more elevated than that of the surrounding tissues. preliminary work showed the interest of this technique. benmiloud and collabortors have shown that the utilization of the "fluobeam" enable to decrease the post total thyroidectomy hypocalcemia rate by a better visualization and preservation of the parathyroid glands. the aim of this study is to evaluate the value of "fluobeam" in the localization, visualization of the parathyroid glands for patients with mild primary hyperparathyroidism.

Eligibility criteria:
inclusion criteria: * adult between 18 and 80 years old. * given signed written informed consent. * patient with moderated and sporadic primary hyperparathyroism (albumin-corrected serum calcium ≤2.85 mmol/l) requiring to be operated on. * patient affiliated to a social security system. exclusion criteria: * underage and adults under guardianship. * pregnant or breast feeding women. * patients with history of cervical radiotherapy or cervicotomy.
chemosensory dysfunction and recovery in endoscopic endonasal skull base surgery

Conditions: Anosmia; Skull Base Neoplasms

Summary: the investigators hypothesize that patients undergoing endoscopic endonasal skull base surgery experience clinically meaningful and modifiable disruptions in postoperative chemosensory function and quality of life, and the investigators further hypothesize that olfactory training in the postoperative period may significantly hasten normalization of patients' chemosensory perturbations. this tailored prospective study seeks to fulfill a significant gap in the understanding of the characteristics, implications, and treatment options for postoperative olfactory and gustatory impairment following endoscopic endonasal skull base surgery.


Eligibility criteria:
inclusion criteria: * english speaking * preoperative diagnosis of benign sellar or parasellar skull base pathology exclusion criteria: * preoperative diagnosis of malignant sellar or parasellar skull base pathology * history of endoscopic sinus surgery * history of skull base surgery * history of radiation therapy or other local treatments for the management of facial, sinonasal, or cranial pathologies * history of chronic rhinosinusitis * history of neurocognitive disorder * history of intrinsic chemosensory pathology * history of cardiac pacemaker * history of gastrectomy
tislelizumab as cross-line treatment for advanced nsclc

Conditions: Advanced Non-small-cell Lung Cancer

Summary: this study is a single-arm, prospective, open phase ii clinical study, exploring the efficacy and safety for advanced non-small cell lung cancer after progression of first-line tislelizumab combined with chemotherapy and continuing tislelizumab in combination with docetaxel. the primary study endpoint of this study is measured by progression-free survival (pfs). 1. tislelizumab: the recommended dose is 200 mg/dose administered every three weeks on the first day of each cycle. 2. docetaxel: 60-75 mg/m2 every 3 weeks, administered on day 1 of each cycle. 3. treatment cycle: tislelizumab in combination with docetaxel until the development of pd, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.


Eligibility criteria:
inclusion criteria: 1. advanced non-small cell lung cancer diagnosed by histology or pathology, and has progressed after first-line treatment with tislelizumab combined with platinum-containing dual-drug chemotherapy 2. patients who have progressed after first-line tislelizumab treatment for more than 3 months 3. no egfr, alk gene mutations (the genetic test is not required for patients with lung squamous cell carcinoma) 4. at least one measurable lesion (recist standard version 1.1) 5. the expected survival period is ≥3 months 6. the ecog-ps score is 0-2 points exclusion criteria: 1. the tumor histology or cytology is confirmed to be mixed adenosquamous carcinoma or combined with small cell lung cancer 2. known or suspected active autoimmune diseases 3. a history of immunodeficiency or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation and history of allogeneic bone marrow transplantation 4. interstitial lung disease, drug-induced pneumonia, radiation pneumonia requiring steroid therapy or clinical symptoms, active pneumonia or severe lung dysfunction 5. symptomatic brain metastases 6. those who are known or suspected to be allergic to test drugs and their excipients 7. women who are pregnant or breastfeeding
magnesium as a mediator of bone and vitamin d metabolism in patients on antiepileptic drug therapy

Conditions: Epilepsy; Magnesium Deficiency; Vitamin D Deficiency

Summary: the objective of this study is to determine the role of magnesium on bone and vitamin d metabolism in patients receiving anti-epileptic medications.


Eligibility criteria:
inclusion criteria: * individuals receiving anti-epileptic drugs as a treatment for epilepsy exclusion criteria: * individuals who are pregnant or breastfeeding, receiving cancer treatments, have liver or kidney diseases, autoimmune diseases, or other diseases that may interfere with vitamin d and magnesium metabolism.